Small molecules remain on target for c-Myc

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The transcription factor c-Myc (myelocytomatosis oncogene) is a critical regulator of cell proliferation, differentiation, and apoptosis.
• Dysregulation of c-Myc is implicated in the development and progression of numerous human cancers.
• Targeting c-Myc directly has been challenging due to its complex regulatory network and lack of enzymatic activity.

Purpose of the Study:

• To investigate the potential of targeting c-Myc's coactivator proteins as a therapeutic strategy for cancer.
• To identify and characterize specific coactivator proteins that are essential for c-Myc function in cancer cells.

Main Methods:

• Utilized proteomic analysis to identify c-Myc interacting proteins.
• Employed gene silencing techniques (e.g., siRNA, shRNA) to inhibit the expression of key coactivator proteins.
• Assessed the impact of coactivator inhibition on c-Myc transcriptional activity, cell proliferation, and apoptosis in various cancer cell lines.

Main Results:

• Successfully identified several novel coactivator proteins that bind to c-Myc.
• Demonstrated that inhibiting specific coactivator proteins significantly reduces c-Myc target gene expression.
• Observed a marked decrease in cancer cell proliferation and induction of apoptosis upon coactivator inhibition.

Conclusions:

• Targeting c-Myc coactivator proteins represents a promising and potentially more tractable strategy for cancer therapy compared to targeting c-Myc directly.
• Further investigation into these coactivator proteins could lead to the development of new anti-cancer drugs.